MA51688A - Protéines prohémostatiques pour le traitement de saignement - Google Patents

Protéines prohémostatiques pour le traitement de saignement

Info

Publication number
MA51688A
MA51688A MA051688A MA51688A MA51688A MA 51688 A MA51688 A MA 51688A MA 051688 A MA051688 A MA 051688A MA 51688 A MA51688 A MA 51688A MA 51688 A MA51688 A MA 51688A
Authority
MA
Morocco
Prior art keywords
bleeding
treatment
prohemostatic
proteins
prohemostatic proteins
Prior art date
Application number
MA051688A
Other languages
English (en)
Inventor
Mettine H A Bos
Pieter H Reitsma
Daniël Verhoef
Original Assignee
Academisch Ziekenhuis Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academisch Ziekenhuis Leiden filed Critical Academisch Ziekenhuis Leiden
Publication of MA51688A publication Critical patent/MA51688A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA051688A 2014-05-26 2015-05-26 Protéines prohémostatiques pour le traitement de saignement MA51688A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14169895 2014-05-26

Publications (1)

Publication Number Publication Date
MA51688A true MA51688A (fr) 2020-12-02

Family

ID=50774744

Family Applications (2)

Application Number Title Priority Date Filing Date
MA051688A MA51688A (fr) 2014-05-26 2015-05-26 Protéines prohémostatiques pour le traitement de saignement
MA40042A MA40042B1 (fr) 2014-05-26 2015-05-26 Protéines prohémostatiques pour le traitement de saignement

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA40042A MA40042B1 (fr) 2014-05-26 2015-05-26 Protéines prohémostatiques pour le traitement de saignement

Country Status (24)

Country Link
US (5) US10537618B2 (fr)
EP (2) EP3744840A1 (fr)
JP (3) JP6640198B2 (fr)
KR (2) KR102245264B1 (fr)
CN (1) CN106536566A (fr)
AU (2) AU2015268149B2 (fr)
CA (1) CA2949349A1 (fr)
DK (1) DK3149163T3 (fr)
EA (2) EA202190813A1 (fr)
ES (1) ES2813440T3 (fr)
HR (1) HRP20201311T1 (fr)
HU (1) HUE052098T2 (fr)
IL (2) IL249132B (fr)
LT (1) LT3149163T (fr)
MA (2) MA51688A (fr)
MX (2) MX378899B (fr)
NZ (1) NZ727444A (fr)
PL (1) PL3149163T3 (fr)
PT (1) PT3149163T (fr)
RS (1) RS60706B1 (fr)
SG (2) SG10201906329VA (fr)
SI (1) SI3149163T1 (fr)
WO (1) WO2015183085A1 (fr)
ZA (1) ZA201608017B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202190813A1 (ru) 2014-05-26 2021-12-31 Академиш Зикенхёйс Лейден Прогемостатические белки для лечения кровотечений
CN108486197B (zh) * 2018-03-06 2021-10-22 爱斯特（成都）生物制药股份有限公司 高纯度依度沙班中间体的制备方法
GB202408056D0 (en) * 2024-06-06 2024-07-24 Cambridge Entpr Ltd Anticoagulant protein molecules and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
ATE158816T1 (de) 1990-11-26 1997-10-15 Genetics Inst Expression von pace in wirtszellen und verfahren zu dessen verwendung
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
EP0519596B1 (fr) 1991-05-17 2005-02-23 Merck & Co. Inc. Procédé pour réduire l'immunogénicité des domaines variables d'anticorps
DE4203965A1 (de) 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
AT404357B (de) 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
DE19605126A1 (de) 1996-02-12 1997-08-14 Basf Ag Thrombinmuteine als Antidot für Thrombininhibitoren
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
EP1728798A1 (fr) 2005-06-01 2006-12-06 ZLB Behring GmbH Polypeptides du facteur X de la coagulation avec propiertés d'activation modifiées
MX2008006313A (es) * 2005-11-15 2008-11-06 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (fr) * 2006-02-21 2007-08-22 CSL Behring GmbH Polypeptides du facteur de coagulation X avec des propriétés d'activation modifiées
CA2683443A1 (fr) * 2007-04-13 2008-10-23 Catalyst Biosciences, Inc. Polypeptides du facteur vii modifies et leurs utilisations
EP2915564B1 (fr) 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Antidotes pour inhibiteurs du facteur XA et procédés d'utilisation associés
TWI465247B (zh) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
ES2605801T3 (es) 2009-07-15 2017-03-16 Portola Pharmaceuticals, Inc. Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
WO2014018120A1 (fr) * 2012-07-25 2014-01-30 Catalyst Biosciences, Inc. Polypeptides modifiés du facteur x et leurs utilisations
ES2761730T3 (es) 2013-01-31 2020-05-20 Pfizer Composiciones y procedimientos para contrarrestar la inhibición del factor Xa
US10119101B2 (en) 2014-04-28 2018-11-06 Ecolab Usa Inc. Method of minimizing enzyme based aerosol mist using a pressure spray system
EA202190813A1 (ru) * 2014-05-26 2021-12-31 Академиш Зикенхёйс Лейден Прогемостатические белки для лечения кровотечений

Also Published As

Publication number Publication date
IL277377B (en) 2021-10-31
JP2017522900A (ja) 2017-08-17
IL277377A (en) 2020-11-30
AU2015268149B2 (en) 2021-03-11
US20200138917A1 (en) 2020-05-07
PL3149163T3 (pl) 2020-12-28
EA202190813A1 (ru) 2021-12-31
AU2015268149A1 (en) 2016-12-08
CN106536566A (zh) 2017-03-22
HRP20201311T1 (hr) 2020-12-11
US20240390467A1 (en) 2024-11-28
IL249132A0 (en) 2017-01-31
CA2949349A1 (fr) 2015-12-03
RS60706B1 (sr) 2020-09-30
SG10201906329VA (en) 2019-08-27
PT3149163T (pt) 2020-09-03
BR112016027649A2 (pt) 2017-08-15
EP3744840A1 (fr) 2020-12-02
EA037991B1 (ru) 2021-06-21
MX378899B (es) 2025-03-10
US20220288172A1 (en) 2022-09-15
LT3149163T (lt) 2020-09-25
EP3149163A1 (fr) 2017-04-05
US11357836B2 (en) 2022-06-14
WO2015183085A1 (fr) 2015-12-03
SG11201609811TA (en) 2016-12-29
ZA201608017B (en) 2019-04-24
KR20210054573A (ko) 2021-05-13
ES2813440T3 (es) 2021-03-23
KR102245264B1 (ko) 2021-04-28
US11304995B2 (en) 2022-04-19
US12083170B2 (en) 2024-09-10
AU2021203838A1 (en) 2021-07-08
EA201692161A1 (ru) 2017-08-31
MX2016015567A (es) 2017-06-29
MX2020013410A (es) 2021-02-26
AU2021203838B2 (en) 2023-03-02
IL249132B (en) 2020-09-30
JP6640198B2 (ja) 2020-02-05
JP2020062039A (ja) 2020-04-23
DK3149163T3 (da) 2020-08-31
KR102351728B1 (ko) 2022-01-14
NZ727444A (en) 2021-12-24
JP7535849B2 (ja) 2024-08-19
US10537618B2 (en) 2020-01-21
HUE052098T2 (hu) 2021-04-28
EP3149163B1 (fr) 2020-06-03
JP2022134139A (ja) 2022-09-14
SI3149163T1 (sl) 2020-10-30
KR20170020332A (ko) 2017-02-22
NZ764611A (en) 2024-07-05
US20200138916A1 (en) 2020-05-07
US20170157223A1 (en) 2017-06-08
MA40042B1 (fr) 2020-08-31

Similar Documents

Publication Publication Date Title
MA47719A (fr) Esketamine pour le traitement de la dépression
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
EP3388004A4 (fr) Instrument de traitement
MA41449A (fr) Polythérapies pour le traitement de cancers
EP3374502A4 (fr) Procédés pour le traitement de dystrophies cornéennes
HUE057817T2 (hu) Anti-LAG-3 antitestek haematológiai malignitások kezelésére
EP3362065A4 (fr) Polythérapie pour le traitement de malignités
HUE059158T2 (hu) Eljárás pridopidin elõállítására
EP3504187A4 (fr) Utilisation de la pridopidine pour le traitement du déclin fonctionnel
EP3351189A4 (fr) Instrument de traitement pour endoscope
EP3288592A4 (fr) Utilisation de cannabidiol pour le traitement de spasmes infantiles
EP3380200A4 (fr) Compositions pour le traitement des cheveux
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
EP3335041A4 (fr) Biomarqueurs pour le traitement de la pelade
EP3400011A4 (fr) Combinaisons anti-cd20 pour le traitement des tumeurs
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
EP3380063A4 (fr) Compositions pour le traitement des cheveux
EP3375108A4 (fr) Traitement dewlan
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
EP3334432A4 (fr) Cerdulatinib pour le traitement du myélome
EP3316887A4 (fr) Inhibiteurs de gls1 pour le traitement de maladies
EP3386967A4 (fr) Combinaisons pour le traitement de calculs rénaux
EP3349793A4 (fr) Anti-s100a8 pour le traitement de la leucémie
EP3318205A4 (fr) Instrument de traitement pour endoscope
EP3503887A4 (fr) Combinaisons pour le traitement du cancer